title: Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
authors.affiliation: University of Essen, West German Cancer Center, Essen, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Heim
authors.forename: M
authors.initials: M
authors.lastname: Sharifi
authors.forename: R A
authors.initials: RA
authors.lastname: Hilger
authors.forename: M E
authors.initials: ME
authors.lastname: Scheulen
authors.forename: S
authors.initials: S
authors.lastname: Seeber
authors.forename: D
authors.initials: D
authors.lastname: Strumberg
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000494:pharmacology*; D002277:Carcinoma / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000473:pathology*; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000009:adverse effects* / Q000494:pharmacology*; D000077157:Sorafenib; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D019908:Proto-Oncogene Proteins c-raf